Medindia

X

BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting

Friday, May 16, 2008 General News J E 4
Advertisement
BRISBANE, Calif., May 15 BiPar Sciences, Inc., a privatelyheld biopharmaceutical company developing novel cancer therapies, todayannounced that data supporting its lead PARP inhibitor, BSI-201, will bepresented at the 2008 American Society of Clinical Oncology annual meeting inChicago.

Findings will be presented from the first in human Phase 1 study ofBSI-201, a small-molecule inhibitor of poly-ADP-ribose polymerase (PARP), as amonotherapy in subjects with advanced solid tumors. BiPar will also present aPhase 1b study evaluating BSI-201 in combination with topotecan, gemcitabine,temozolomide and carboplatin/paclitaxel in subjects with advanced solidtumors. The primary objective of these respective studies is to assess thesafety profile of BSI-201 when used as a monotherapy and in combination withcytotoxic chemotherapy in subjects with measurable disease.

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus onexploring novel mechanisms of action in oncology. The lead development programis based on DNA repair, specifically with poly ADP-ribose polymerase (PARP)inhibitors. The lead product within that program is BSI-201, a platform drugwith the potential to be a superior new treatment across a range of tumortypes, both as monotherapy and in combination with chemotherapy. The companyis currently testing BSI-201 in a range of Phase 2 trials in breast, brain andovarian cancer.The schedule of poster presentations is as follows: Title: First in Human Phase 1 Study of BSI-201, a Small Molecule Inhibitor of Poly ADP-ribose polymerase (PARP) in Subjects with Advanced Solid Tumors When: Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session Abstract#: 3577 Title: A Phase 1B Study Evaluating BSI-201 in Combination with Chemotherapy in Subjects with Advanced Solid Tumors When: Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session Abstract #: 3579

SOURCE BiPar Sciences, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Medivation Announces Presentation of MDV3100 Clini...
S
Release of Cytopia Abstract for CYT997 Oral Presen...